Osteoclastogenesis inhibitory factor exhibits hypocalcemic effects in normal mice and in hypercalcemic nude mice carrying tumors associated with humoral hypercalcemia of malignancy

Bone

Volumn 23, Issue 6, 1998, Pages 495-498

  Akatsu, T ^a   Murakami, T ^a   Ono, K ^a   Nishikawa, M ^a   Tsuda, E ^b   Mochizuki, S I ^b   Fujise, N ^b   Higashio, K ^b   Motoyoshi, K ^a   Yamamoto, M ^a   Nagata, N ^a  

^a NATIONAL DEFENSE MEDICAL COLLEGE   (Japan)

^b SNOW BRAND MILK PRODUCTS CO LTD   (Japan)

Author keywords

Humoral hypercalcemia of malignancy; Hypercalcemia; Osteoclast differentiation factor; Osteoclastogenesis inhibitory factor; Osteoprotegerin

Indexed keywords

CALCIUM; CREATININE; GROWTH INHIBITOR; HUMORAL ANTIBODY; OSTEOPROTEGERIN; PHOSPHATE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CALCIUM BLOOD LEVEL; CELL GROWTH; CONTROLLED STUDY; HYPERCALCEMIA; HYPOCALCEMIA; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; MALIGNANT NEOPLASTIC DISEASE; MOUSE; NONHUMAN; NUDE MOUSE; OSTEOCLAST; OSTEOLYSIS; PHOSPHATE BLOOD LEVEL; URINARY EXCRETION;

ANIMALS; CALCIUM; CREATININE; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; GLYCOPROTEINS; HYPERCALCEMIA; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASM PROTEINS; NEOPLASMS, EXPERIMENTAL; OSTEOPROTEGERIN; PARATHYROID HORMONE-RELATED PROTEIN; PHOSPHATES; PROTEINS; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RECEPTORS, TUMOR NECROSIS FACTOR; RECOMBINANT PROTEINS; TRANSFORMING GROWTH FACTOR ALPHA;

EID: 0032404069     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/S8756-3282(98)00141-0     Document Type: Article

References (16)

1. Akatsu, T., Murakami, T., Nishikawa, M., Ono, K., Shinomiya, N., Tsuda, E., Mochizuki, S., Yamaguchi, K., Kinosaki, M., Higashio, K., Yamamoto, M., Motoyoshi, K., and Nagata, N. Osteoclastogenesis inhibitory factor suppresses osteoclast survival by interfering the interaction of stromal cells with osteoclast. Res. Commun., in press.
2. Anderson D.M., Maraskovsky E., Billingsley W.L., Dougall W.C., Tometsko M.E., Roux E.R., Teepe M.C., DuBose R.F., Cosman D., Galibert L. A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. Nature. 390:1997;175-179.
3. Goltzman D., Henderson J.E. Expression of PTHrP in disease. Bilezikian J.P., Raisz L.G., Rodan G.A. Principles of Bone Biology. 1996;809-826 Academic, San Diego, CA.
4. Horwood N.J., Udagawa N., Elliott J., Grail D., Okamura H., Kurimoto M., Dunn A.R., Martin T.J., Gillespie M. Interleukin 18 inhibits osteoclast formation via T cell production of granulocyte macrophage colony-stimulating factor. J Clin Invest. 101:1998;595-603.
5. Lacey D.L., Timms E., Tan H.L., Kelley M.J., Dunstan C.R., Burgess T., Elliott R., Colombero A., Elliott G., Scully S., Hsu H., Sullivan J., Hawkins N., Davy E., Capparelli C., Eli A., Qian Y.X., Kaufman S., Sarosi I., Shalhoub V., Senaldi G., Guo J., Delaney J., Boyle W.J. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell. 93:1998;165-176.
6. Mundy G.R. Role of cytokines, parathyroid hormone, and growth factors in malignancy. Bilezikian J.P., Raisz L.G., Rodan G.A. Principles of Bone Biology. 1996;827-836 Academic, San Diego, CA.
7. Nagata N., Akatsu T., Kugai N., Yasutomo Y., Kinoshita T., Kosano H., Shimauchi T., Takatani O., Ueyama Y. The tumor cells (FA-6) established from a pancreatic cancer associated with humoral hypercalcemia of malignancy A simultaneous production of parathyroid hormone-like activity and transforming growth factor activity . Endocrinologica Japonica. 36:1989;75-85.
8. Sato K., Satoh T., Shizume K., Yamakawa Y., Ono Y., Demura H., Akatsu T., Takahashi N., Suda T. Prolonged decrease of serum calcium concentrations by murine γ-interferon in hypercalcemic, human tumor (EC-GI)-bearing nude mice. Cancer Res. 52:1992;444-449.
9. Sato K., Yamakawa Y., Shizume K., Satoh T., Nohtomi K., Demura H., Akatsu T., Nagata N., Kasahara T., Ohkawa H., Ohsumi K. Passive immunization with anti-parathyroid hormone-related protein monoclonal antibody markedly prolongs survival time of hypercalcemic nude mice bearing transplanted human PTHrP-producing tumors. J Bone Miner Res. 8:1993;849-860.
10. Simonet W.S., Lacey D.L., Dunstan C.R., Kelley M., Chang M.S., Luthy R., Nguyen H.Q., Wooden S., Bennett L., Boone T., Shimamoto G., DeRose M., Elliott R., Colombero A., Tan H.L., Trail G., Sullivan J., Davy E., Bucay N., Renshaw-Gegg L., Hughes T.M., Hill D., Pattison W., Campbell P., Sander S., Van G., Tarpley J., Derby P., Lee R., Boyle W.J. Amgen EST program. Osteoprotegerin: A novel secreted protein involved in the regulation of bone density. Cell. 89:1997;309-319.
11. Tsuda E., Goto M., Mochizuki S., Yano K., Kobayashi F., Morinaga T., Higashio K. Isolation of a novel cytokine from human fibroblasts that specifically inhibits osteoclastogenesis. Biochem Biophys Res Commun. 234:1997;137-142.
12. Wong B.R., Josien R., Lee S.Y., Sauter B., Li H.L., Steinman R.M., Choi Y. TRANCE (tumor necrosis factor [TNF]-related activation-induced cytokine), a new TNF family member predominantly expressed in T cells, is a dendritic cell-specific survival factor. J Exp Med. 186:1997;2075-2080.
13. Wong B.R., Rho J., Arron J., Robinson E., Orlinick J., Chao M., Kalachikov S., Cayani E., Bartlett F.S. III, Frankel W.N., Lee S.Y., Choi Y. TRANCE is a novel ligand of the tumor necrosis factor receptor family that activates c-Jun N-terminal kinase in T cells. J Biol Chem. 272:1997;25190-25194.
14. Yamaguchi K., Kinosaki M., Goto M., Kobayashi F., Tsuda E., Morinaga T., Higashio K. Characterization of structural domains of human osteoclastogenesis inhibitory factor. J Biol Chem. 273:1998;5117-5123.
15. Yasuda H., Shima N., Nakagawa N., Mochizuki S., Yano K., Fujise N., Sato Y., Goto M., Yamaguchi K., Kuriyama M., Kanno T., Murakami A., Tsuda E., Morinaga T., Higashio K. Identity of osteoclastogenesis inhibitory factor (OCIF) and osteopretegerin (OPG) A mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro . Endocrinology. 139:1998;1329-1337.
16. Yasuda H., Shima N., Nakagawa N., Yamaguchi K., Kinosaki M., Mochizuki S., Tomoyasu A., Yano K., Goto M., Murakami A., Tsuda E., Morinaga T., Higashio K., Udagawa N., Takahashi N., Suda T. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor. and is identical to TRANCE/RANKL. Proc Natl Acad Sci USA. 95:1998;3597-3602.